evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

193 questions · 193 findings · 70 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 52 · 26.9%GRADE not reported 9 · 4.7%Very low 58 · 30.1%Low 40 · 20.7%Moderate 30 · 15.5%High 4 · 2.1%

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

Fluoroquinolones vs beta‐lactams

Serious adverse events clinical criteria · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).

1 finding from 1 review

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).

1 finding from 1 review

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).

1 finding from 1 review